Amgen Expands Hep C Agreement With Three Rivers To China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Three Rivers Pharmaceuticals has signed a definitive licensing agreement with Amgen to acquire further commercial rights, including China, for the hepatitis C drug Infergen, the company announced Sept. 1